

Article

Rhodium(III)-Catalyzed [4+2] Annulation via C-H Activation: Synthesis of Multi-Substituted Naphthalenone Sulfoxonium Ylides

Xiaohan Song ^{1,2}, Xu Han ^{1,2}, Rui Zhang ^{1,2}, Hong Liu ^{1,2,*} and Jiang Wang ^{1,2,*}

- State Key Laboratory of Drug Research and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; xiaohanpharm@163.com (X.S.); dtchx_cbdml@hotmail.com (X.H.); ruipharmacy@163.com (R.Z.)
- ² University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China
- * Correspondence: hliu@simm.ac.cn (H.L.); jwang@simm.ac.cn (J.W.); Tel.: +86-50807042 (H.L.)

Academic Editor: Il Kim Received: 28 April 2019; Accepted: 14 May 2019; Published: 16 May 2019



Abstract: A convenient Rh(III)-catalyzed C-H activation and cascade [4+2] annulation for the synthesis of naphthalenone sulfoxonium ylides has been developed. This method features perfect regioselectivity, mild and redox-neutral reaction conditions, and broad substrate tolerance with good to excellent yields. Preliminary mechanistic experiments were conducted and a plausible reaction mechanism was proposed. The new type naphthalenone sulfoxonium ylides could be further transformed into multi-substituted naphthols, which demonstrates the practical utility of this methodology.

Keywords: rhodium(III); sulfoxonium ylides; naphthols

1. Introduction

Substituted naphthols have been characterized as crucial organic motifs and are embedded in various pharmaceuticals and natural products such as rifampicin [1–3], gossypol [4–6], dioncophylline A [7–9], propranolol [10–13], and naftopidil [14–16] (Figure 1). As a result, the development of efficient methods to synthesize multi-substituted naphthols is important [17–20]. Over the past few years, transition-metal-catalyzed C–H activation has been demonstrated to be a convenient strategy to establish aromatic and heteroaromatic skeletons [21–24]. Nevertheless, the synthetic approach for multi-substituted naphthols is scarcely reported [25–29]. For example, it can be synthesized by the Rh(III)-catalyzed cross-coupling of benzoylates with diphenylacetylene (Scheme 1a) [25–27]. Recently, Li and co-workers have demonstrated a strategy using phosphonium ylides and diazo compounds to access naphthol derivatives [29]. Thus, development of an efficient, straightforward route to the naphthol framework is highly desired.





Figure 1. Representative compounds with a 1-naphthol moiety.

Previous work

(a) Reports of the approaches to substituted naphthol



(b) Recent advances in the synthesis of bis-substituted sulfoxonium ylide



Scheme 1. (a) Reports of approaches to substituted naphthol; (b) Recent advances in the synthesis of bis-substituted sulfoxonium ylide.

Recently, sulfoxonium ylides have been identified as a precursor of carbenoid in the transition-metal-catalyzed reactions [30–32]. Being successfully applied to the multi-kilogram synthesis of drug intermediates via Ir(I)-catalyzed reactions in industry [33,34] sulfoxonium ylides have also been widely investigated in the Rh(III)- [35–44], Co(III)- [45], or Ru(II)-catalyzed [46,47] C-H bond functionalization. However, the application of sulfoxonium ylides is severely limited by its substrate scope because the C1 position substitution in the ylide center is only H. To overcome such limitations, Bayer and co-workers reported the synthesis of bis-substituted sulfoxonium ylides via rhodium-catalyzed coupling of iodonium ylides with sulfoxides (Scheme 1b) [48]. Burtoloso et al. described another strategy to access α -aryl- β -keto sulfoxonium ylides using aryne [49]. Furthermore, Aïssa et al. developed a palladium-catalyzed C–H cross-coupling of α -ester sulfoxonium ylides with aryl halide to afford the (hetero)aryl-substituted sulfoxonium ylides, which expanded the scope of the substitution in the ylide center [50]. However, the synthetic approach for cyclic sulfoxonium ylides remains unexplored.

A seminal work reported by Li and co-workers revealed that sulfoxonium ylides could serve as weak directing-groups to participate in C-H activation [27,51]. Inspired by the previous work, we report a Rh(III)-catalyzed C-H activation and [4+2] annulation to afford the naphthalenone sulfoxonium ylides and its synthetic utility is further demonstrated through simple reactions to access multi-substituted naphthols. It is worth mentioning that, during our submission, Fan's group also reported a very similar approach to the synthesis of naphthalenone sulfoxoniums [52].

2. Results and Discussion

We initiated our studies with model substrates sulfoxonium ylide **1a** and diazo compound **2a** to investigate the optimal reaction conditions (Table 1). Initially, transition-metal catalysts (Ru(II), Co(III), Ir(III), and Rh(III)), which could potentially trigger the cross-coupling of **1a** with **2a**, were screened to demonstrate the feasibility of this method (entries 1–4). To our delight, the target molecule naphthalenone sulfoxonium ylide **3aa** could be obtained in a moderate yield of 65% in the presence of [Cp*RhCl₂]₂ and AgSbF₆ under air condition at r.t. for 12 h. Several typical additives, including PivOH, CsOAc, Zn(OTf)₂, Cu(OAc)₂, and Zn(OAc)₂, were subsequently explored (entries 5–9), and Zn(OAc)₂ exhibited the best additive for this annulation, because a more powerful catalyst Cp*Rh(OAc) could be formed after adding Zn(OAc)₂ [42], while CsOAc and Zn(OTf)₂ could not afford compound **3aa** at all. Subsequent Ag salt screening revealed that replacement of AgSbF₆ by AgNTf₂ decreased the yield (entry 10). Encouraged by these results, we further screened the solvent and found that TFE, MeOH, and MeCN reduced the reaction conversion (entries 11–13). The optimal results could be achieved when sulfoxonium ylide (**1a**, 0.2 mmol) and diazo compounds (**2a**, 0.44 mmol) were treated with the catalytic system of [Cp*RhCl₂]₂ (5 mol%), AgSbF₆ (30 mol%), and Zn(OAc)₂ (30 mol%) in DCE at room temperature for 12 h.



Table 1. Optimization of the reaction conditions ^a.

^a Reaction conditions: **1a** (0.2 mmol), **2a** (0.24 mmol), catalyst (5 mol%), Ag salt (20 mol%), additive (30 mol%), in solvent (3 mL), tube for 12 h at room temperature. ^b Yield determined by ¹H NMR. ^c Cp* = 1,2,3,4,5-pentamethylcyclopenta-1,3-diene. ^d DCE = dichloroethane. ^e TFE = trifluoroethanol. ^f N.R. = No reaction. ^g Yield of the isolated product.

With the optimal reaction conditions in hand, we started to explore the generality and scope of sulfoxonium ylides (1a–1j) by performing the annulation with diazo compound 2a (Scheme 2). It was found that this reaction could tolerate various substrates with both electron-donating and electron-withdrawing substituents in the sulfoxonium ylides system, and afforded the corresponding naphthalenone sulfoxonium ylides in good to excellent yields (3aa–3da, 44–96%). Generally, sulfoxonium ylides with electron-donating substituents gave higher yields compared with electron-withdrawing substituents. To further investigate the effect of substituted group of the sulfoxonium yield, several moieties were independently introduced at the para-position of the phenyl ring while the ortho-position was blocked by chlorine. As a result, the naphthalenone sulfoxonium ylides were obtained in good to excellent yields (3ja–3la, 84–94%). It is worth noting that using ortho-non-substituted benzoyl sulfoxonium ylides (1m–1p) with 2a, the dialkylated product could be obtained in good yields (3ma–3pa, 59–76%).



Scheme 2. Scope of sulfoxonium ylides ^{a, b}. ^a Reaction conditions: **1** (0.2 mmol), **2a** (0.22 mmol), $[Cp*RhCl_2]_2$ (5 mol%), AgSbF₆ (20 mol%), and Zn(OAc)₂ (30 mol%) in DCE (2 mL) at r.t. for 12 h under air condition. ^b Yield of the isolated product. ^c Reaction conditions: sulfoxonium ylide **1** (0.2 mmol), diazo compound **2a** (0.44 mmol), $[Cp*RhCl_2]_2$ (5 mol%), AgSbF₆ (20 mol%), and Zn(OAc)₂ (30 mol%) in DCE (2 mL) at 60 °C for 4 h under air condition.

Next, in order to expand the utility of this reaction, we investigated the scope and generality of the diazo compounds (Scheme 3). Diazo compounds with the electron-donating and halogen groups at the para-position of its phenyl ring (R²) resulted in good to excellent yields of corresponding products (**3ab–3ad** and **3af**, 79–95%), while electron-withdrawing group led to poor yield (**3ae**, 53%). The structure of product **3ac** was confirmed by X-ray crystallography (CCDC 1899265). It should be mentioned that the substituents of diazo compounds at the different positions of its phenyl ring (R²) did not alter the reaction efficiency, provided the desired products in high yields (**3ag–3aj**, 77%–84%). Moreover, when R² was replaced by methyl or cyclopropyl the yields are 91% and 72%, respectively (**3ak** and **3al**), which indicated that increasing of the steric hindrance of R² group decreased the yield

of this reaction. At the same time, R³ groups with the large steric hindrance were well tolerated in this reaction (**3am** and **3an**, 89% and 61%).



Scheme 3. Scope of diazo compounds ^{a,b}. ^a Reaction conditions: sulfoxonium ylide **1a** (0.2 mmol), diazo compounds **2** (0.22 mmol), [Cp*RhCl₂]₂ (5 mol%), AgSbF₆ (20 mol%), and Zn(OAc)₂ (30 mol%) in DCE (2 mL) at r.t. for 12 h under air condition. ^b Yield of the isolated product. ^c Determined by single X-ray crystal structure analysis.

To further assess synthetic utility of the reaction, a gram-scale reaction between **1a** and **2a** has been performed, and the product **3aa** was isolated with a 79% yield (Scheme 4a). Moreover, as a versatile structural motif, the synthetic application of the naphthalenone sulfoxonium ylides has been investigated. Naphthalenone sulfoxonium ylide **3ak** was transformed to the tetra-substituted α -naphthol **5ak**, of which the skeleton was embedded in rifampicin [1–3], via Ir(II)-catalyzed amination in a moderate yield of 45% (Scheme 4b) [49]. In addition, compound **3ak** was reduced to sulfoxide **6ak** in a good yield of 65%, which could be used to synthesize the FabH inhibitor [51,53], (Scheme 4c).



(a) H/D exchange



Scheme 4. (a) Gram-scale synthesis of compound 3aa; (b) Synthetic applications of 3ak.

To obtain more insight into the mechanism of this annulation, a series of experiments were performed (Scheme 5). First, a hydrogen–deuterium exchange experiment of **1a** was carried out using CD₃OD under the standard conditions (Scheme 5a). Compound **1a** underwent slight H/D exchange in the presence of the Rh(III) catalyst, indicating the reversibility of the C(aryl)–H bond cleavage. To further probe the C-H activation process, the kinetic isotopic effect (KIE) studies with separate kinetic experiments were performed to gain insights into the rate-determining step for this cross-coupling reaction (Scheme 5b). The KIE was determined by performing intermolecular competition experiments using an equimolar mixture of **1a** and **1a-d**₇ in the couplings with **2k** under standard conditions. The KIE value was 2.8, which was observed on the basis of the ¹H NMR analysis (see supplementary materials), indicating that the C–H activation was involved in the turnover-limiting step.

47% D [CpRhCl₂]₂ 5 mol% H/D 0 AgSbF₆ 20 mol% CD₃OD 10 ea Zn(OAc)₂ 30 mol% H/D 8% D DCE r.t. 12h 1a (b) KIE experiment standard conditions 1a 2k KIE = 2.8 standard conditions 2k 3ak-d₆ 1a-d7

Scheme 5. (a) H/D exchange experiment of 1a; (b) KIE experiment.

Based on these preliminary mechanistic investigations, a plausible reaction mechanism for the formation of naphthalenone sulfoxonium ylide **3aa** is proposed in Scheme 6. Initially, oxygen coordination of **1a** is followed by cyclometalation to deliver a five-membered rhodacyclic intermediate **A**. Then, the nucleophilic C(aryl)–Rh species further attacks the diazo compound **2a** to generate Rh(III) carbene species **B** with the loss of N₂. The resulting species **B** further undergoes carbene migratory insertion to furnish another six-membered rhodacyclic intermediate **C**. Protonolysis of the Rh–C bond by HX releases the key intermediate **D** with the regeneration of the active Rh(III) catalyst. Finally, intermediate **D** undergoes a sequential aldol condensation to form the desired product **3aa**.



Scheme 6. Proposed reaction mechanism.

3. Materials and Methods

3.1. General Information

The reagents (chemicals) were purchased from commercial sources, and used without further purification. Analytical thin layer chromatography (TLC) was HSGF 254 (0.15–0.2 mm thickness). All products were characterized by their NMR and MS spectra. The ¹H- (500 MHz) and ¹³C-NMR (125 MHz) spectra were recorded in deuterochloroform (CDCl3) on Bruker Avance III spectrometer (Billerica, MA, USA). Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), or multiplet (m). Low-resolution mass spectra (LRMS) were measured on Agilent 1260 Infinity II (Palo Alto, CA, USA). High-resolution mass spectra (HRMS) were measured on Agilent 1290-6545 UHPLC-QTOF respectively (Palo Alto, CA, USA).

3.2. Experimental Part Method

3.2.1. General Procedure for the Preparation of Sulfoxonium Ylides 1a-1p

Sulfoxonium ylides **1a–1p** were prepared according to the reported procedures [28]. To a stirred solution of potassiumtert-butoxide (3.3 equiv.) in THF was added trimethylsulfoxonium iodide (3.0 equiv.) at room temperature. The resulting mixture is refluxed for 2 h. Then reaction mixture was cooled to 0 °C, followed by the addition of acyl chlorides (1.0 equiv.) in THF. The reaction was

9 of 17

allowed to reach room temperature and stirred for 3 h. Next, the solvent was evaporated, and water and ethylacetate were added to the resulting slurry. The layers were separated and the aqueous layer was washed with ethyl acetate and the organic layers were combined. The organic solution was dried over anhydrous sodium sulphate (Na₂SO₄), filtered over a sintered funnel, and evaporated to dryness. The crude product was purified by flash chromatography over silica gel using DCM/MeOH (95:5) to afford the corresponding sulfoxonium ylides **1a–1p**.

3.2.2. General Procedure for the Preparation of α-Diazocarbonyl Compounds 2a-2n

The α -diazocarbonyl compounds **2a**–**2n** were prepared according to the reported procedures [29]. To a solution of β -ketoester or β -diketone (1.0 equiv.) and *N*-(4-azidosulfonylphenyl)acetamide (1.2 equiv.) in CH₃CN at 0 °C was added DBU (1.2 equiv.). The resulting solution was stirred at 0 °C for 3 h and slowly brought to room temperature. Upon completion, as indicated by thin layer chromatography (TLC), the reaction was quenched with water, extracted with ethyl acetate, and dried over anhydrous Na₂SO₄. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by column chromatography using *n*-hexane/EtOAc (92:8) to afford corresponding α -diazocarbonyl compounds **2a–2n**.

3.2.3. General Procedures for the Products 3aa-3la, 3ab-3an (Compound 3aa as the Example)

A tube was charged with $[Cp*RhCl_2]_2$ (6.0 mg, 5 mol%), AgSbF₆ (14 mg, 20 mol%), Zn(OAc)₂ (14 mg, 30 mol%), sulfoxonium ylide (1a, 0.2 mmol), α -diazocarbonyl compound (2a, 0.24 mmol), and DCE (3 mL). The reaction mixture was stirred at room temperature for 12 h under air condition. After that, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using DCM/MeOH (98:2) to afford the product **3aa** as a light yellow solid.

3.2.4. General Procedures for the Products 3ma-3pa (Compound 3ma as the Example)

A tube was charged with [Cp*RhCl₂] $_2$ (6.0 mg, 5 mol%), AgSbF₆ (14 mg, 20 mol%), Zn(OAc) $_2$ (14 mg, 30 mol%), sulfoxonium ylide (1m, 0.2 mmol), α -diazocarbonyl compound (2a, 0.44 mmol), and DCE (3 mL). The reaction mixture was stirred at 60 °C for 4 h under air condition. After that, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using DCM/MeOH (98:2) to afford the product **3ma** as a light yellow solid.

3.2.5. Gram-Scale Synthesis of Compound 3aa

A round bottomed flask was charged with $[Cp*RhCl_2]_2$ (147 mg, 238 µmol), AgSbF₆ (327 mg, 951 µmol), Zn(OAc)₂ (262 mg, 1.43 mmol), sulfoxonium ylide (1a, 4.76 mmol), α -diazocarbonyl compound (2a, 1.25 g, 5.71 mmol). Dichloroethane (35 mL) was then added to the reaction mixture and stirring was turned on. The reaction mixture was stirred at r.t. for 12 h under air condition. After that, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using DCM/MeOH (99:1) to afford the product **3aa** (1.45 g, 79%, light yellow solid).

3.2.6. Synthesis of Compound 5ak

To a 15 mL microwave glass tube containing a magnetic stirrer and fitted with a Teflon cap, sulfoxonium ylide 3ak (64 mg, 1.0 equiv.), *p*-methoxyaniline 4 (24 mg, 2.0 equiv.), $[Ir(COD)Cl]_2$ (3 mg, 2.5 mol%), and toluene (1 mL) were added. The mixture was stirred for 1 h at 150 °C under microwave irradiation. Then, the organic solvent was removed in a rotary evaporator and the crude product purified by flash chromatography (petroleum ether: ethyl acetate = 10:1).

3.2.7. Synthesis of Compound 6ak

A mixture of **3ak** (64 mg, 1 equiv.) and NaH (60%, dispersion in paraffin liquid) (28 mg, 0.7 mmol, 3.5 equiv.) was added to a Schlenk tube equipped with a stir bar. Dry THF (1.0 mL) was added and the

mixture was stirred at 80 °C for 24 h under Ar atmosphere. Then, the organic solvent was removed in a rotary evaporator and the crude product was purified by flash chromatography (petroleum ether: ethyl acetate = 10:1).

3.2.8. Mechanistic Studies

A tube was charged with $[Cp*RhCl_2]_2$ (6.0 mg, 5 mol%), AgSbF₆ (14 mg, 20 mol%), Zn(OAc)₂ (14 mg, 30 mol%), sulfoxonium ylide (1a, 0.2 mmol), CD₃OD (72 mg, 10 equiv.), and DCE (3 mL). The reaction mixture was stirred at r.t. for 12 h under air condition. After that, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using DCM/MeOH (96:4) to afford the product, which was characterized by ¹H NMR spectroscopy. ¹H NMR analysis of **1a** revealed 47% deuteration at the 6-position of phenyl ring and 8% deuteration at the α -position of the carbonyl.

Two tubes were charged with $[Cp*RhCl_2]_2$ (6.0 mg, 5 mol%), AgSbF₆ (14 mg, 20 mol%), Zn(OAc)₂ (14 mg, 30 mol%), sulfoxonium ylide (**1a** or **1a**–*d*₇, 0.2 mmol), α -diazocarbonyl compounds (**2k**, 0.24 mmol) and DCE (3 mL). The reaction mixture was stirred at r.t. for 2 h under air condition. After that, the solvent was removed under reduced pressure and the residue was purified by silica gel chromatography using DCM/MeOH (99:1) to afford the product. The KIE value was determined to be $k_H/k_D = 2.8$ on the basis of ¹H NMR analysis.

3.3. Product Characterization

Ethyl 3-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-methyl-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3aa**): light yellow solid; m.p.:182–184 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.51 (d, J = 8.3 Hz, 1H), 7.43 (dd, J = 8.3, 7.1 Hz, 1H), 7.38–7.31 (m, 5H), 7.17 (d, J = 7.1, 1H), 3.92 (q, J = 7.1 Hz, 2H), 3.77 (s, 6H), 2.99 (s, 3H), 0.90 (t, J = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 176.1, 169.3, 139.5, 137.3, 136.9, 135.9, 130.2, 129.2, 128.8, 128.6, 127.4, 127.2, 123.1, 118.4, 98.3, 60.8, 44.2, 24.4, 13.7. LRMS (ESI): 381.4 [M – H]⁺. HRMS (ESI) calculated for C₂₁H₂₀O₄S [M – H]⁺: 381.1166; found: 381.1177.

Ethyl 5-chloro-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ba**): light yellow solid; m.p.: 225–226 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.57 (dd, *J* = 6.4, 3.1 Hz, 1H), 7.41–7.37 (m, 3H), 7.35–7.31 (m, 3H), 7.31–7.26 (m, 2H), 3.90 (q, *J* = 7.1 Hz, 2H), 3.79 (s, 6H), 0.88 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 172.7, 168.3, 138.1, 136.7, 135.7, 132.6, 129.9, 128.6, 128.2, 127.2, 126.8, 125.6, 123.7, 117.4, 99.1, 60.5, 43.9, 13.1. LRMS (ESI): 403.3 [M – H]⁺. HRMS (ESI) calculated for C₂₁H₁₉ClO₄S [M – H]⁺: 403.0765; found: 403.0774.

Ethyl 5-bromo-3-(dimethyl(oxo)-λ⁶-sulfanylidene)-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ca**): light yellow solid; m.p.: 203-204 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.66 (d, *J* = 7.6 Hz, 1H), 7.62 (d, *J* = 8.3 Hz, 1H), 7.42–7.23 (m, 6H), 3.89 (q, *J* = 7.1 Hz, 2H), 3.76 (s, 6H), 0.87 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 172.9, 168.7, 138.5, 137.1, 136.3, 132.5, 130.6, 129.1, 127.6, 127.2, 126.6, 124.8, 120.2, 117.7, 99.2, 61.0, 44.2, 13.6. LRMS (ESI): 447.2 [M – H]⁺. HRMS (ESI) calculated for $C_{21}H_{19}BrO_4S$ [M – H]⁺: 447.0260; found: 447.0254.

Ethyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-4-oxo-2-phenyl-5-(trifluoromethyl)-3,4-dihydronaphthalene-1-carboxylate (**3da**): light yellow solid; m.p.: 228-230 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.91 (d, *J* = 8.4 Hz, 1H), 7.86 (d, *J* = 7.6 Hz, 1H), 7.61 (t, *J* = 7.9 Hz, 1H), 7.41–7.30 (m, 5H), 3.98–3.85 (q, *J* = 7.2 Hz, 2H), 3.79 (s, 6H), 0.89 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 172.0, 168.8, 139.2, 136.4, 136.2, 129.6, 129.3, 129.0, 127.7 (q, *J*_{C-F} = 31.0 Hz), 127.7, 127.3, 125.2 (q, *J*_{C-F} = 8.2 Hz), 124.5 (*J*_{C-F} = 271.0 Hz), 117.4, 100.2, 61.0, 43.8, 13.6. ¹⁹F NMR (470 MHz, Chloroform-d) δ -56.9. LRMS (ESI): 459.2 [M – H]⁺. HRMS (ESI) calculated for C₂₂H₁₉F₃O₄S [M + Na]⁺: 459.0848; found: 459.0857.

Ethyl 5-chloro-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-7-methyl-4-oxo-2-phenyl-3,4-dihydronaphthalene-1 -carboxylate (**3ea**): light yellow solid; m.p.: 212–214 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.42–7.27

11 of 17

(m, 6H), δ 7.24 (d, *J* = 1.6 Hz, 1H). 3.89 (q, *J* = 7.1 Hz, 2H), 3.75 (s, 6H), 2.40 (s, 3H), 0.86 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 173.0, 168.9, 141.0, 138.6, 137.1, 136.4, 132.8, 130.2, 129.1, 127.6, 127.2, 124.0, 123.7, 117.6, 99.0, 61.0, 44.4, 21.5, 13.6. LRMS (ESI): 417.4 [M – H]⁺. HRMS (ESI) calculated for C₂₂H₂₁ClO₄S [M – H]⁺: 417.0922; found: 417.0927.

Ethyl 5-chloro-3-(dimethyl(oxo)-λ6-sulfanylidene)-7-fluoro-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3fa**): light yellow solid; m.p.: 208–210 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.37–7.32 (m, 3H), 7.30–7.24 (m, 3H), 7.17 (dd, J = 8.3, 2.5 Hz, 1H), 3.87 (q, J = 7.1 Hz, 2H), 3.77 (s, 6H), 0.86 (t, J = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 172.2, 167.9, 161.8 (d, $J_{C-F} = 251.6$ Hz), 139.8, 137.9 (d, $J_{C-F} = 10.4$ Hz), 135.6, 134.7 (d, $J_{C-F} = 11.8$ Hz), 128.4, 127.3, 126.8, 122.6, 117.0 (d, $J_{C-F} = 26.3$ Hz), 116.8 (d, $J_{C-F} = 3.7$ Hz), 108.5 (d, $J_{C-F} = 22.2$ Hz), 99.3, 60.7, 43.9, 13.1. ¹⁹F NMR (470 MHz, Chloroform-d) δ –108.2. LRMS (ESI): 421.2 [M – H]⁺. HRMS (ESI) calculated for C₂₁H₁₈FClO₄S [M – H]⁺: 421.0676; found: 421.0671.

Ethyl 5,7-dichloro-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ga**): light yellow solid; m.p.: 215–217 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.55 (d, *J* = 1.9 Hz, 1H), 7.37–7.31 (m, 4H), 7.29–7.25 (m, 3H), 3.87 (q, *J* = 7.1 Hz, 2H), 3.75 (s, 6H), 0.85 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 172.6, 168.3, 140.2, 137.7, 136.0, 135.9, 134.3, 129.0, 128.4, 127.8, 127.3, 124.4, 123.3, 116.8, 100.4, 61.2, 44.2, 13.6. LRMS (ESI): 437.2 [M – H]⁺. HRMS (ESI) calculated for C₂₁H₁₈Cl₂O₄S [M – H]⁺: 437.0382; found: 437.0376.

Ethyl 5-chloro-3-(dimethyl(oxo)-λ⁶-sulfanylidene)-7-methoxy-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ha**): light yellow solid; m.p.: 217–218 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.35–7.25 (m, 5H), 7.03 (d, *J* = 2.5 Hz, 1H), 6.96 (d, *J* = 2.5 Hz, 1H), 3.86 (q, *J* = 7.1 Hz, 2H), 3.83(s, 3H), 3.72 (s, 6H), 0.85 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (150 MHz, Chloroform-d) δ 172.7, 168.8, 160.1, 139.5, 138.3, 136.4, 134.3, 128.9, 127.5, 127.1, 120.5, 118.1, 117.1, 105.1, 98.4, 60.8, 55.4, 44.3, 13.5. LRMS (ESI): 433.3 [M – H]+. HRMS (ESI) calculated for $C_{22}H_{21}ClO_5S$ [M – H]+: 433.0871; found: 433.0874.

Ethyl 5-chloro-3-(dimethyl(oxo)-λ⁶-sulfanylidene)-4-oxo-2-phenyl-7-(trifluoro-methyl)-3,4dihydronaphthalene-1-carboxylate (**3ia**): light yellow solid; m.p.: 212–214 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.85 (d, *J* = 1.8 Hz, 1H), 7.57 (d, *J* = 1.8 Hz, 1H), 7.37 (dd, *J* = 4.9, 2.3 Hz, 3H), 7.32–7.25 (m, 2H), 3.91 (q, *J* = 7.0 Hz, 2H), 3.79 (s, 6H), 0.88 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 172.4, 168.1, 140.5, 136.9, 135.7, 134.4, 131.8 (q, *J* = 33.1 Hz), 128.9, 128.2 (q, *J* = 274.7 Hz) 127.9, 127.6, 127.3, 124.1 (q, *J* = 3.3 Hz), 121.3 (q, *J* = 4.3 Hz), 117.5, 101.7, 61.3, 44.1, 13.5. ¹⁹F NMR (470 MHz, Chloroform-d) δ –63.1. LRMS (ESI): 471.3 [M – H]⁺. HRMS (ESI) calculated for C₂₂H₁₈ClF₃O₄S [M – H]⁺: 471.0639; found: 471.0644.

Ethyl 6-bromo-5-chloro-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ja**): light yellow solid; m.p.: 232–234 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.74 (d, *J* = 8.9 Hz, 1H), 7.46 (d, *J* = 8.9 Hz, 1H), 7.38–7.34 (m, 3H), 7.32–7.29 (m, 2H), 3.89 (q, *J* = 7.1 Hz, 2H), 3.79 (s, 6H), 0.87 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 172.3, 168.4, 139.4, 136.0, 134.7, 132.5, 129.0, 127.8, 127.6, 127.3, 124.8, 122.7, 117.4, 100.7, 61.1, 44.3, 13.6. LRMS (ESI): 480.8 [M – H]⁺. HRMS (ESI) calculated for C₂₁H₁₉BrClO₄S [M – H]⁺: 480.9870; found: 48 0.9866.

Ethyl 5-chloro-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-6-methyl-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ka**): light yellow solid; m.p.: 230–232 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.50 (d, *J* = 8.4 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 7.38–7.29 (m, 5H), 3.93–3.87 (q, *J* = 7.1 Hz 2H), 3.79 (s, 6H), 2.52 (s, 3H), 0.88 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 173.3, 168.9, 137.7, 136.4, 135.4, 135.1, 133.0, 132.3, 129.1, 127.5, 127.2, 126.3, 123.3, 117.7, 99.7, 60.9, 44.5, 21.1, 13.6. LRMS (ESI): 416.9 [M – H]⁺.HRMS (ESI) calculated for C₂₂H₂₂ClO₄S [M – H]⁺: 417.0922; found: 417.0922.

Ethyl 5-chloro-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-8-methoxy-4-oxo-2-phenyl-3,4-dihydronaphthalene -1-carboxylate (**3la**): light yellow solid; m.p.: 225–227 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.35–7.26 (m, 6H), 6.90 (d, *J* = 8.5 Hz, 1H), 3.82 (q, 2H), 3.81 (s, 3H), 3.73 (s, 6H), 0.96 (t, *J* = 7.1 Hz, 3H). ¹³C

NMR (150 MHz, Chloroform-d) δ 172.4, 169.3, 153.7, 138.1, 135.3, 129.8, 128.5, 128.2, 127.5, 127.1, 126.9, 124.6, 114.6, 111.7, 100.5, 60.5, 56.7, 44.0, 13.9. LRMS (ESI): 432.9 [M – H]⁺. HRMS (ESI) calculated for C₂₂H₂₂ClO₅S [M – H]⁺: 433.0871; found: 433.0882.

Ethyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-5-(1-ethoxy-1,3-dioxo-3-phenylpropan-2-yl)-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3ma**): light yellow solid; m.p.: 88–90 °C; ¹H NMR (400 MHz, Chloroform-d) δ 8.08–8.00 (m, 2H), 7.95 (s, 1H), 7.64 (d, *J* = 8.3 Hz, 1H), 7.55–7.30 (m, 9H), 7.17 (d, *J* = 7.3 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 3.91 (q, *J* = 7.2 Hz, 2H), 3.66 (s, 3H), 3.65 (s, 3H), 1.27 (t, *J* = 7.1 Hz, 3H), 0.89 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 195.4, 175.0, 170.4, 169.0, 137.6, 136.7, 136.6, 136.1, 133.8, 132.9, 130.2, 129.3, 129.2, 129.0, 128.5, 127.6, 127.2, 126.9, 125.3, 118.4, 99.5, 61.2, 60.9, 58.5, 44.0, 43.9, 14.2, 13.7. LRMS (ESI): 559.3 [M – H]⁺, HRMS (ESI) calculated for C₃₂H₃₁O₇S [M – H]⁺: 559.1785; found: 559.1793.

Ethyl 3-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-(1-ethoxy-1,3-dioxo-3-phenylpropan-2-yl)-7-methoxy-4-oxo -2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3na**): light yellow solid; m.p.: 95–97 °C; ¹H NMR (400 MHz, Chloroform-d) δ 8.03 (d, *J* = 7.4 Hz, 2H), 7.92 (s, 1H), 7.55–7.48 (m, 1H), 7.45–7.31 (m, 7H), 7.02 (d, *J* = 2.5 Hz, 1H), 6.80 (d, *J* = 2.4 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 3.89 (q, *J* = 7.1 Hz, 2H), 3.80 (s, 3H), 3.66 (s, 3H), 1.27 (t, *J* = 7.1 Hz, 3H), 0.88 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (150 MHz, Chloroform-d) δ 195.2, 174.7, 170.2, 169.2, 160.4, 138.6, 138.0, 136.8, 136.6, 135.8, 132.9, 129.2, 129.1, 129.0, 128.5, 127.6, 127.3, 121.5, 118.0, 117.9, 105.6, 98.2, 61.3, 60.9, 58.4, 55.2, 44.4, 44.2, 14.3, 13.7. LRMS (ESI): 589.0 [M – H]⁺. HRMS (ESI) calculated for C₃₃H₃₃O₈S [M – H]⁺: 589.1891; found: 589.1870.

Ethyl 7-(tert-butyl)-3-(dimethyl(oxo)-l6-sulfanylidene)-5-(1-ethoxy-1,3-dioxo-3-phenylpropan-2-yl)-4-oxo-2-phenyl-3,4-dihydronaphthalene-1-carboxylate (**3oa**): light yellow solid; m.p.: 110–112 °C; ¹H NMR (400 MHz, Chloroform-d) δ 8.05–7.98 (m, 2H), 7.93 (s, 1H), 7.56 (d, *J* = 1.8 Hz, 1H), 7.50 (t, *J* = 7.5 Hz, 1H), 7.42-7.30 (m, 7H), 7.20 (d, *J* = 1.8 Hz, 1H), 4.28 (qd, *J* = 7.1, 3.3 Hz, 1H), 3.95 (q, *J* = 7.1 Hz, 2H), 3.70 (s, 3H), 3.69 (s, 2H), 1.29 (t, *J* = 7.1 Hz, 3H), 1.24 (s, 9H), 0.96 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 195.8, 174.9, 170.4, 169.1, 152.9, 137.4, 136.9, 136.7, 135.9, 133.3, 132.6, 129.3, 129.2, 129.0, 128.4, 127.6, 127.3, 126.8, 120.9, 118.7, 98.7, 61.1, 60.8, 58.7, 44.3, 44.1, 35.0, 30.8, 14.3, 13.8. LRMS (ESI): 615.0 [M – H]⁺. HRMS (ESI) calculated for C₃₆H₃₉O₇S [M – H]⁺: 615.2411; found: 615.2396.

Ethyl 7-bromo-3-(dimethyl(oxo)-l6-sulfanylidene)-5-(1-ethoxy-1,3-dioxo-3-phenylpropan-2-yl)-4-oxo-2 -phenyl-3,4-dihydronaphthalene-1-carboxylate (**3pa**): light yellow solid; m.p.: 113–115 °C; ¹H NMR (400 MHz, Chloroform-d) δ 8.03 (d, J = 7.7 Hz, 2H), 7.88–7.77 (m, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.6 Hz, 3H), 7.41–7.30 (m, 5H), 4.28 (q, J = 7.1 Hz, 2H), 3.91 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 3.66 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 194.5, 174.6, 169.8, 168.5, 139.0, 137.3, 136.7, 136.2, 135.8, 133.0, 130.3, 129.2, 129.1, 128.9, 128.6, 127.8, 127.7, 127.3, 125.5, 125.1. 117.5. 100.0, 61.5, 61.1, 58.1, 44.1, 14.2, 13.6. LRMS (ESI): 636.8 [M – H]⁺. HRMS (ESI) calculated for C₃₂H₃₀BrO₇S [M – H]⁺: 637.0890; found: 637.0903.

Ethyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-2-(4-fluorophenyl)-5-methyl-4-oxo-3,4-dihydronaphthalene-1 -carboxylate (**3ab**): light yellow solid; m.p.: 217–218 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.47 (dd, *J* = 8.5, 1H), 7.42 (dd, *J* = 8.3, 7.1 Hz, 1H), 7.31-7.26 (m, 2H), 7.16 (d, *J* = 7.0, 1H), 7.07–7.01 (m, 1H), 3.95 (q, *J* = 7.1 Hz, 2H), 3.75 (s, 6H), 2.97 (s, 3H), 0.96 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 175.6, 168.7, 161.8 (d, *J* _{C-F} = 246.3 Hz), 139.1, 135.6, 135.3, 132.1 (d, *J* _{C-F} = 3.5 Hz), 130.4 (d, *J* _{C-F} = 8.0 Hz), 129.8, 128.4, 128.3, 122.6, 118.4, 113.7 (*J* _{C-F} = 21.5 Hz), 97.6, 60.4, 43.9, 23.9, 13.3. ¹⁹F NMR (470 MHz, Chloroform-d) δ –144.6. LRMS (ESI): 401.2 [M – H]⁺. HRMS (ESI) calculated for C₂₂H₂₁FO₄S [M – H]⁺: 401.1223; found: 401.1226.

Ethyl 2-(4-chlorophenyl)-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-5-methyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3ac**): light yellow solid; m.p.: 199–201°C; ¹H NMR (400 MHz, Chloroform-d) δ 7.45 (d, *J* = 8.2 Hz, 1H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.29 (d, *J* = 8.1 Hz, 2H), 7.22 (d, *J* = 8.2 Hz, 2H), 7.14 (d, *J* = 7.0 Hz, 1H), 3.93 (q, *J* = 7.1 Hz, 2H), 3.69 (s, 6H), 2.94 (s, 3H), 0.93 (t, *J* = 7.1 Hz, 3H). ¹³C NMR

 $(125 \text{ MHz}, \text{Chloroform-d}) \ \delta \ 176.0, \ 169.1, \ 139.6, \ 135.9, \ 135.8, \ 135.3, \ 133.4, \ 130.6, \ 130.3, \ 128.8, \ 127.4, \ 123.1, \ 118.7, \ 98.0, \ 60.9, \ 44.2, \ 24.3, \ 13.7. \ \text{LRMS} \ (\text{ESI}): \ 417.2 \ [\text{M} - \text{H}]^+. \ \text{HRMS} \ (\text{ESI}) \ \text{calculated for} \ C_{22}\text{H}_{21}\text{ClO}_4\text{S} \ [\text{M} - \text{H}]^+: \ 417.0922; \ \text{found:} \ 417.0927.$

Ethyl 2-(4-bromophenyl)-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-5-methyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3ad**): light yellow solid, 88 mg, yield: 95%. m.p.: 217–219 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.49–7.44 (m, 3H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.19–7.08 (m, 3H), 3.92 (q, *J* = 7.1 Hz, 2H), 3.67 (s, 6H), 2.94 (s, 3H), 0.93 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 175.9, 169.0, 139.6, 135.9, 135.8, 135.8, 130.9, 130.3, 128.9, 123.1, 121.6, 118.5, 98.0, 60.9, 44.2, 24.4, 13.7. LRMS (ESI): 459.2 [M – H]⁺. HRMS (ESI) calculated for C₂₂H₂₁BrO₄S [M – H]⁺: 459.0271; found: 459.0263.

Ethyl 3-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-methyl-4-oxo-2-(4-(trifluoromethyl)ph-enyl)-3,4dihydronaphthalene-1-carboxylate (**3ae**): light yellow solid; m.p.: 202–204 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.61 (d, *J* = 8.0 Hz, 2H), 7.50 (d, *J* = 8.2 Hz, 1H), 7.45 (d, *J* = 7.8 Hz, 3H), 7.19 (d, *J* = 7.0 Hz, 1H), 3.91 (q, *J* = 7.1 Hz, 2H), 3.75 (s, 6H), 2.98 (s, 3H), 0.87 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 176.1, 168.9, 140.8, 139.7, 135.8, 135.7, 130.4, 129.7, 129.3 (q, *J*_{C-F} = 92.4 Hz), 129.0, 124.2 (q, *J*_{C-F} = 270.3 Hz), 124.0 (q, *J*_{C-F} = 8.2 Hz), 123.2, 118.6, 97.6, 60.9, 44.2, 24.4, 13.5. ¹⁹F NMR (470 MHz, Chloroform-d) δ -62.4. LRMS (ESI): 451.2 [M – H]⁺. HRMS (ESI) calculated for $C_{23}H_{21}F_3O_4S$ [M – H]⁺: 451.1185; found: 451.1184.

Ethyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-2-(4-methoxyphenyl)-5-methyl-4-oxo-3,4-dihydronaphthalene -1-carboxylate (**3af**): light yellow solid, 78 mg, yield: 95%. m.p.: 152–154 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.50–7.46 (m, 1H), 7.42 (dd, *J* = 8.3, 7.1 Hz, 1H), 7.25 (d, *J* = 8.6 Hz, 2H), 7.15 (dt, *J* = 7.1, 1.0 Hz, 1H), 6.90 (d, *J* = 8.6 Hz, 2H), 3.96 (q, *J* = 7.1 Hz, 2H), 3.84 (s, 3H), 3.76 (s, 6H), 2.98 (s, 3H), 0.97 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 176.1, 169.4, 158.9, 139.5, 136.9, 135.8, 130.2, 130.1, 128.9, 128.7, 128.5, 122.9, 118.8, 112.6, 98.3, 60.8, 55.2, 44.3, 24.4, 13.8. LRMS (ESI): 413.3 [M – H]⁺, HRMS (ESI) calculated for C₂₃H₂₄O₅S [M – H]⁺: 413.1417; found: 413.1420.

Ethyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-2-(3-methoxyphenyl)-5-methyl-4-oxo-3,4-dihydronaphthalene -1-carboxylate (**3ag**): light yellow solid; m.p.: 80–82 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.49 (d, *J* = 8.2 Hz, 1H), 7.41 (dd, *J* = 8.3, 7.1 Hz, 1H), 7.30–7.21 (m, 1H), 7.14 (d, *J* = 7.1 Hz, 1H), 6.94–6.85 (m, 3H), 3.95 (q, *J* = 7.1 Hz, 2H), 3.80 (s, 3H), 3.70 (d, *J* = 2.6 Hz, 6H), 2.97 (s, 3H), 0.93 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 176.1, 169.3, 158.6, 139.5, 138.2, 137.0, 135.8, 130.2, 128.8, 128.1, 123.0, 122.0, 118.1, 115.3, 112.8, 98.3, 60.8, 55.2, 44.2, 24.4, 13.7. LRMS (ESI): 413.3 [M – H]⁺, HRMS (ESI) calculated for C₁₉H₂₄O₄S [M – H]⁺: 413.1417; found: 413.1427.

Ethyl 2-(3-bromophenyl)-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-5-methyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3ah**) light yellow solid; m.p.: 90–92 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.49–7.43 (m, 3H), 7.43–7.37 (m, 1H), 7.25–7.16 (m, 1H), 7.16–7.11 (m, 1H), 3.94 (q, *J* = 7.1 Hz, 2H), 3.70 (s, 3H), 3.69 (s, 3H), 2.94 (s, 3H), 0.94 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 175.5, 168.5, 139.1, 138.4, 135.3, 135.1, 131.7, 129.9, 129.8, 128.5, 128.2, 127.6, 122.7, 120.7, 118.1, 97.4, 60.5, 43.8, 43.7, 23.9, 13.3. HRMS (ESI) calculated for C₂₂H₂₁BrO₄S [M – H]⁺: 461.0417; found: 461.0427.

Ethyl 2-(2-chlorophenyl)-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-5-methyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3ai**): light yellow solid; m.p.: 86–88 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.54 (d, *J* = 8.1 Hz, 1H), 7.44–7.34 (m, 2H), 7.32–7.21 (m, 3H), 7.15 (d, *J* = 7.2 Hz, 1H), 3.96–3.82 (m, 2H), 3.81 (s, 3H), 3.71 (s, 3H), 2.97 (s, 3H), 0.90 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 175.2, 168.4, 139.1, 135.7, 135.4, 134.0, 133.9, 130.2, 129.6, 128.7, 128.5, 127.8, 125.5, 123.0, 117.5, 96.7, 60.3, 43.5, 41.6, 24.0, 13.2. HRMS (ESI) calculated for C₂₂H₂₁BrO₄S [M – H]⁺: 417.0922; found: 417.0931.

Ethyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-2-(2-methoxyphenyl)-5-methyl-4-oxo-3,4-dihydronaphthalene -1-carboxylate (**3aj**): light yellow solid; m.p.: 210–212 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.59–7.54 (m, 1H), 7.38 (dd, *J* = 8.3, 7.2 Hz, 1H), 7.33 (td, *J* = 7.9, 1.8 Hz, 1H), 7.21 (dd, *J* = 7.4, 1.7 Hz, 1H), 7.13 (dt, *J* = 7.2, 1.1 Hz, 1H), 6.96 (td, *J* = 7.4, 1.1 Hz, 1H), 6.87 (dd, *J* = 8.3, 1.0 Hz, 1H), 3.97–3.83 (m, 2H), 3.81 (s,

14 of 17

3H), 3.74 (s, 3H), 3.73 (s, 3H), 2.98 (s, 3H), 0.89 (t, J = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 174.8, 168.9, 157.0, 138.9, 135.8, 133.8, 129.3, 129.3, 128.7, 128.4, 128.0, 125.9, 122.7, 119.8, 117.5, 109.4, 97.9, 60.1, 55.2, 43.4, 41.3, 24.0, 13.2. LRMS (ESI): 413.3 [M – H]⁺. HRMS (ESI) calculated for C₂₃H₂₄O₅S [M – H]⁺: 413.1417; found: 413.1421.

Ethyl 3-(dimethyl(oxo)-λ⁶-sulfanylidene)-2,5-dimethyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3ak**): light yellow solid; m.p.: 146–148 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.37–7.32 (m, 1H), 7.28 (d, *J* = 6.2 Hz, 1H), 7.06 (d, *J* = 7.1 Hz, 1H), 4.43 (q, *J* = 7.1 Hz, 2H), 3.80 (s, 6H), 2.90 (s, 3H), 2.43 (s, 3H), 1.40 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-d) δ 175.6, 170.1, 138.8, 135.8, 132.6, 129.4, 127.6, 127.5, 117.4, 98.1, 60.7, 44.2, 23.8, 16.3, 13.8. LRMS (ESI): 321.2 [M – H]⁺. HRMS (ESI) calculated for C₁₇H₂₀O₄S [M – H]⁺: 321.1155; found: 321.1157.

Ethyl 2-cyclopropyl-3-(dimethyl(oxo)- λ^6 -sulfanylidene)-5-methyl-4-oxo-3,4-dihy-dronaphthalene-1-carboxylate (**3al**): light yellow solid; m.p.: 180–182 °C; ¹H NMR (500 MHz, Chloroform-d) δ 7.47 (d, *J* = 8.3 Hz, 1H), 7.35 (dd, *J* = 8.4, 7.2 Hz, 1H), 7.07 (dt, *J* = 7.1, 1.2 Hz, 1H), 4.42 (q, *J* = 7.2 Hz, 2H), 3.81 (d, *J* = 2.4 Hz, 6H), 2.89 (s, 3H), 2.25 (tt, *J* = 8.6, 5.9 Hz, 1H), 1.41 (t, *J* = 7.2 Hz, 2H), 0.93 (dd, *J* = 8.4, 1.7 Hz, 2H), 0.64 (dd, *J* = 5.9, 1.7 Hz, 2H). ¹³C NMR (125 MHz, Chloroform-d) δ 175.6, 170.0, 139.2, 138.7, 135.7, 129.2, 128.1, 127.9, 122.1, 118.2, 99.7, 60.6, 44.0, 23.9, 13.86, 13.72, 8.3. LRMS (ESI): 331.4 [M – H]⁺. HRMS (ESI) calculated for C₁₉H₂₄O₄S [M – H]⁺: 331.1010; found: 331.1011.

Isopropyl 3-(dimethyl(oxo)- λ^6 -sulfanylidene)-2,5-dimethyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3am**): light yellow solid; m.p.: 148–150 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.35 (t, *J* = 7.6 Hz, 1H), 7.29 (d, *J* = 7.4 Hz, 1H), 7.05 (d, *J* = 7.0 Hz, 1H), 5.35 (hept, *J* = 5.7 Hz, 1H), 3.79 (s, 6H), 2.89 (s, 3H), 2.44 (s, 3H), 1.40 (d, *J* = 6.3 Hz, 6H). ¹³C NMR (125 MHz, Chloroform-d) δ 176.3, 170.1, 139.3, 136.3, 132.8, 129.8, 128.2, 127.9, 122.3, 118.0, 98.3, 68.7, 44.6, 24.3, 21.9, 16.6. LRMS (ESI): 335.3 [M – H]⁺. HRMS (ESI) calculated for C₁₈H₂₂O₄S [M – H]⁺: 335.1312; found: 335.1308.

Tert-butyl 3-(dimethyl(oxo)-λ⁶-sulfanylidene)-2,5-dimethyl-4-oxo-3,4-dihydronaphthalene-1-carboxylate (**3an**): light yellow solid; m.p.: 152–154 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.35 (d, *J* = 4.1 Hz, 2H), 7.05 (s, 1H), 3.80 (s, 6H), 2.88 (s, 3H), 2.45 (s, 3H), 1.63 (s, 9H). ¹³C NMR (125 MHz, Chloroform-d) δ 176.0, 169.9, 139.3, 136.4, 132.1, 129.8, 128.1, 127.9, 122.3, 119.4, 98.2, 81.7, 44.7, 28.3, 24.3, 16.5. LRMS (ESI): 349.3 [M – H]⁺. LRMS (ESI): 349.4 [M – H]⁺, HRMS (ESI) calculated for C₁₉H₂₄O₄S [M – H]⁺: 349.1468; found: 349.1472.

Ethyl 4-hydroxy-3-((4-methoxyphenyl)amino)-2,5-dimethyl-1-naphthoate (**5ak**): green oil, 33 mg, yield: 35%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.15 (s, 1H), 7.43 (d, *J* = 8.4 Hz, 1H), 7.34 (dd, *J* = 8.6, 6.9 Hz, 1H), 7.19 (d, *J* = 6.9 Hz, 1H), 6.96 (s, 1H), 6.74 (d, *J* = 8.9 Hz, 2H), 6.45 (d, *J* = 8.9 Hz, 2H), 4.39 (q, *J* = 7.1 Hz, 2H), 3.63 (s, 3H), 2.88 (s, 3H), 2.11 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 169.8, 154.0, 152.3, 141.6, 135.7, 133.3, 130.6, 127.8, 126.9, 123.7, 123.4, 122.6, 122.3, 115.0, 114.9, 61.3, 55.7, 25.2, 16.0, 14.5. LRMS (ESI): 364.4 [M – H]⁺, HRMS (ESI) calculated for C₂₂H₂₃NO₄ [M – H]⁺: 364.1154; found: 364.1157.

Ethyl 4-hydroxy-2,5-dimethyl-3-(methylsulfinyl)-1-naphthoate (**6ak**): white solid, 40 mg, yield: 65%. m.p.: 128–130 °C. ¹H NMR (500 MHz, Chloroform-*d*) δ 12.33 (s, 1H), 7.53–7.48 (m, 1H), 7.43 (dd, *J* = 8.5, 7.0 Hz, 1H), 7.23 (dt, *J* = 7.0, 1.1 Hz, 1H), 4.51 (q, *J* = 7.2 Hz, 2H), 3.05 (s, 3H), 2.96 (s, 3H), 2.37 (s, 3H), 1.45 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (125 MHz, Chloroform-*d*) δ 169.5, 162.9, 137.5, 133.9, 129.0, 129.0, 128.0, 124.5, 124.2, 114.5, 61.6, 39.4, 25.1, 16.0, 14.3. LRMS (ESI): 306.5 [M – H]⁺, HRMS (ESI) calculated for C₁₆H₁₈O₄S [M – H]⁺: 308.0853; found: 308.0854.

4. Conclusions

In summary, we developed a novel method to access naphthalenone sulfoxonium ylides via Rh(III)-catalyzed C-H activation and [4+2] annulation of sulfoxonium ylides with diazo compounds. High regioselectivity, mild and redox-neutral reaction conditions, and wide substrate tolerance

make this protocol efficient to prepare various naphthalenone sulfoxonium ylides. Moreover, the new type of naphthalenone sulfoxonium ylides could be further transformed into multi-substituted naphthols smoothly, which may find important applications in the synthesis of natural products and biologically-active molecules.

Supplementary Materials: The Supplementary Materials are available online.

Author Contributions: Conceptualization: X.S.; experiments and analyses: X.S., X.H., and R.Z; writing—original draft preparation: X.S.; writing—review and editing: J.W. and H.L.

Accession Codes: CCDC 1899265 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

Funding: This research was funded by the National Natural Science Foundation of China (nos. 21632008, 21672231, 21877118, and 81620108027) and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12040107 and XDA12040201) for financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Radner, D.B. Toxicologic and Pharmacologic Aspects of Rifampin. Chest 1973, 64, 213–216. [CrossRef]
- 2. Rzepecki, W.M.; Lodziak, A. Pre- and Postoperative Treatment of Chronic Multiresistant Cases of Pulmonary Tuberculosis with Rifampicin. *Chemotherapy* **1974**, *20*, 120–124. [CrossRef]
- Jean-Baptiste, E.; Blanchemain, N.; Neut, C.; Chai, F.; Maton, M.; Martel, B.; Hildebrand, H.; Haulon, S. Evaluation of the anti-infectious properties of polyester vascular prostheses functionalised with cyclodextrinS. *J. Infect.* 2014, *68*, 116–124. [CrossRef]
- 4. Lin, T.S.; Schinazi, R.; Griffith, B.P.; August, E.M.; Eriksson, B.H.F.; Zheng, D.K.; Prusoff, W.H. Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol. *Antimicrob. Agents Chemother* **1989**, *33*, 2149–2151. [CrossRef] [PubMed]
- 5. Meyers, A.I.; Willemsen, J.J. The synthesis of (S)-(+)-gossypol via an asymmetric Ullmann coupling. *Chem. Commun.* **1997**, 1573–1574. [CrossRef]
- 6. Shelley, M.D.; Hartley, L.; Groundwater, P.W.; Fish, R.G. Structure-activity studies on gossypol in tumor cell lines. *Anti-Cancer Drug* **2000**, *11*, 209–216. [CrossRef]
- Bringmann, G.; Gramatzki, S.; Grimm, C.; Proksch, P. Feeding deterrency and growth retarding activity of the naphthylisoquinoline alkaloid dioncophylline A against Spodoptera littoralis. *Phytochemistry* 1992, *31*, 3821–3825. [CrossRef]
- 8. Bringmann, G.; Saeb, W.; Koppler, D.; Francois, G. Jozimine A ('dimeric' dioncophylline A), a non-natural michellamine analog with high antimalarial activity. *Tetrahedron* **1996**, *52*, 13409–13418. [CrossRef]
- Bringmann, G.; Holenz, J.; Wiesen, B.; Nugroho, B.W.; Proksch, P. Dioncophylline A as a Growth-Retarding Agent against the Herbivorous Insect Spodoptera littoralis: Structure–Activity Relationships. *J. Nat. Prod.* 1997, 60, 342–347. [CrossRef]
- 10. Black, J.W.; Duncan, W.A.M.; Shanks, R.G. Comparison of some properties of pronethalol and propranolol. *Brit. J. Pharmacol.* **1965**, 25, 577–591. [CrossRef]
- 11. Kornfeld, E.C. Chapter 6. Antihypertensive Agents. Annu. Rep. Med. Chem. 1966, 59-66.
- 12. Crowther, A.F.; Smith, L.H. Beta-Adrenergic blocking agents. II. Propranolol and related 3-amino-1-naphthoxy-2-propanols. *J. Med. Chem.* **1968**, *11*, 1009–1013. [CrossRef]
- 13. Schwender, C.F.; Farber, S.; Blaum, C.; Shavel, J. Derivatives of 3,4-dihydro-1(2H)-naphthalenone as beta.-adrenergic blocking agents. 1. Bunolol and related analogs. *J. Med. Chem.* **1970**, *13*, 684–688. [CrossRef]
- Ikunobu, M.; Kyozo, Y.; Shigeru, K. Pharmacological Profile of the Novel α-Adrenoceptor Antagonist KT-611 (Naftopidil). *Jpn. J. Pharmacol.* **1991**, *55*, 391–398.
- 15. Farthing, M.J.E.; Alstead, M.; Abrams, S.M.; Haug, G.; Johnston, A.; Hermann, R.; Hermann, G.; Ruus, P.; Molz, K.H.; Turner, P. Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. *Posgrad. Med. J.* **1994**, *70*, 363–366. [CrossRef]

- 16. Violetta, C.; Fausto, S.; Oriana, T.; Arnaldo, F. (1,4-Benzothiazinyloxy) alkylpiperazine derivatives as potential antihypertensive agents. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 465–468.
- 17. de Koning, C.B.; Rousseau, A.L.; van Otterlo, W.A. Modern methods for the synthesis of substituted naphthalenes. *Tetrahedron* **2003**, *59*, 7–36. [CrossRef]
- Mulrooney, C.A.; Li, X.; DiVirgilio, E.S.; Kozlowski, M.C. General Approach for the Synthesis of Chiral Perylenequinones via Catalytic Enantioselective Oxidative Biaryl Coupling. J. Am. Chem. Soc. 2003, 125, 6856–6857. [CrossRef]
- Dohi, T.; Takenaga, N.; Nakae, T.; Toyoda, Y.; Yamasaki, M.; Shiro, M.; Fujioka, H.; Maruyama, A.; Kita, Y. Asymmetric Dearomatizing Spirolactonization of Naphthols Catalyzed by Spirobiindane-Based Chiral Hypervalent Iodine Species. J. Am. Chem. Soc. 2013, 135, 4558–4566. [CrossRef]
- 20. Pu, L. Asymmetric Functional Organozinc Additions to Aldehydes Catalyzed by 1,1'-Bi-2-naphthols (BINOLs). *Acc. Chem. Res.* **2014**, 47, 1523–1535. [CrossRef]
- 21. Patureau, F.W.; Besset, T.; Kuhl, N.; Glorius, F. Diverse Strategies toward Indenol and Fulvene Derivatives: Rh-Catalyzed C–H Activation of Aryl Ketones Followed by Coupling with Internal Alkynes. *J. Am. Chem. Soc.* **2011**, *133*, 2154–2156. [CrossRef]
- 22. Ackermann, L. Carboxylate-Assisted Ruthenium-Catalyzed Alkyne Annulations by C–H/Het–H Bond Functionalizations. *Acc. Chem. Res.* 2014, 47, 281–295. [CrossRef]
- 23. Zhu, R.; Farmer, M.E.; Chen, Y.; Yu, J. A Simple and Versatile Amide Directing Group for C–H Functionalizations. *Angew. Chem. Int. Ed.* **2016**, *55*, 10578–10599. [CrossRef] [PubMed]
- 24. Yu, S.; Liu, S.; Lan, Y.; Wan, B.; Li, X. Rhodium-Catalyzed C–H Activation of Phenacyl Ammonium Salts Assisted by an Oxidizing C–N Bond: A Combination of Experimental and Theoretical Studies. *J. Am. Chem. Soc.* **2015**, *137*, 1623–1631. [CrossRef]
- 25. Tan, X.; Liu, B.; Li, X.; Li, B.; Xu, S.; Song, H.; Wang, B. Rhodium-Catalyzed Cascade Oxidative Annulation Leading to Substituted Naphtho[1,8-bc]pyrans by Sequential Cleavage of C(sp2)–H/C(sp3)–H and C(sp2)–H/O–H Bonds. *J. Am. Chem. Soc.* **2012**, *134*, 16163–16166. [CrossRef]
- Zhou, S.; Wang, J.; Wang, L.; Song, C.; Chen, K.; Zhu, J. Enaminones as Synthons for a Directed C–H Functionalization: RhIII-Catalyzed Synthesis of Naphthalenes. *Angew. Chem. Int. Ed.* 2016, 55, 9384–9388. [CrossRef]
- 27. Xu, Y.; Yang, X.; Zhou, X.; Kong, L.; Li, X. Rhodium(III)-Catalyzed Synthesis of Naphthols via C–H Activation of Sulfoxonium Ylides. *Org. Lett.* **2017**, *19*, 4307–4310. [CrossRef]
- 28. Xie, F.; Yu, S.; Qi, Z.; Li, X. Nitrone Directing Groups in Rhodium(III)-Catalyzed C–H Activation of Arenes: 1,3-Dipoles versus Traceless Directing Groups. *Angew. Chem. Int. Ed.* **2016**, *55*, 15351–15355. [CrossRef]
- 29. Li, Y.; Wang, Q.; Yang, X.; Xie, F.; Li, X. Divergent Access to 1-Naphthols and Isocoumarins via Rh(III)-Catalyzed C-H Activation Assisted by Phosphonium *Ylide*. *Org. Lett.* **2017**, *19*, 3410. [CrossRef]
- Barday, M.; Janot, C.; Halcovitch, N.R.; Muir, J.; Aissa, C. Cross-Coupling of α-Carbonyl Sulfoxonium Ylides with C–H Bonds. *Angew. Chem. Int. Ed.* 2017, *56*, 13117–13121. [CrossRef] [PubMed]
- 31. Bayer, A.; Vaitla, J. Synthesis Sulfoxonium Ylide Derived Metal Carbenoids in Organic. *Synthesis* **2018**, *51*, 612–628.
- 32. Wu, X.; Sun, S.; Yu, J.; Cheng, J. Recent Applications of α-Carbonyl Sulfoxonium Ylides in Rhodium- and Iridium-Catalyzed C–H Functionalizations. *Synlett.* **2018**, *30*, 21–29.
- Mangion, I.K.; Ruck, R.T.; Rivera, N.; Huffman, M.A.; Shevlin, M. A Concise Synthesis of a β-Lactamase Inhibitor. Org. Lett. 2011, 13, 5480–5483. [CrossRef]
- Molinaro, C.; Bulger, P.G.; Lee, E.E.; Kosjek, B.; Lau, S.; Gauvreau, D.; Howard, M.E.; Wallace, D.J.; O'Shea, P.D. CRTH2 Antagonist MK-7246: A Synthetic Evolution from Discovery through Development. *J. Org. Chem.* 2012, 77, 2299–2309. [CrossRef]
- 35. Xu, Y.; Zhou, X.; Zheng, G.; Li, X. Sulfoxonium Ylides as a Carbene Precursor in Rh(III)-Catalyzed C–H Acylmethylation of Arenes. *Org. Lett.* **2017**, *19*, 5256–5259. [CrossRef] [PubMed]
- 36. Chen, R.; Cui, S. Rh(III)-Catalyzed C–H Activation/Cyclization of Benzamides and Diazonaphthalen-2(1H)-ones for Synthesis of Lactones. *Org. Lett.* **2017**, *19*, 4002–4005. [CrossRef]
- Hu, P.; Zhang, Y.; Liu, B.; Li, X. Facile construction of hydrogenated azepino[3,2,1-hi]indoles by Rh(III)-catalyzed C-H activation/[5+2] annulation of N-cyanoacetylindolines with sulfoxonium ylides. Org. Chem. Front. 2018, 5, 3263–3266. [CrossRef]

- Xiao, Y.; Xiong, H.; Sun, S.; Yu, J.; Cheng, J. Rh(III)-Catalyzed dual C–H functionalization of 3-(1H-indol-3-yl)-3-oxopropanenitriles with sulfoxonium ylides or diazo compounds toward polysubstituted carbazoles. Org. Biomol. Chem. 2018, 16, 8715–8718. [CrossRef]
- 39. Zheng, G.; Tian, M.; Xu, Y.; Chen, X.; Li, X. Rhodium(III)-catalyzed annulative coupling between arenes and sulfoxonium ylides via C–H activation. *Org. Chem. Front.* **2018**, *5*, 998–1002. [CrossRef]
- 40. Halskov, K.S.; Witten, M.R.; Hoang, G.L.; Mercado, B.Q.; Ellman, J.A. Rhodium(III)-Catalyzed Imidoyl C–H Activation for Annulations to Azolopyrimidines. *Org. Lett.* **2018**, *20*, 2464–2467. [CrossRef]
- 41. Hu, P.; Zhang, Y.; Xu, Y.; Yang, S.; Liu, B.; Li, X. Construction of (Dihydro)naphtho[1,8-bc]pyrans via Rh(III)-Catalyzed Twofold C–H Activation of Benzoylacetonitriles. *Org. Lett.* **2018**, *20*, 2160–2163. [CrossRef]
- 42. Wu, X.; Xiong, H.; Sun, S.; Cheng, J. Rhodium-Catalyzed Relay Carbenoid Functionalization of Aromatic C–H Bonds toward Fused Heteroarenes. *Org. Lett.* **2018**, *20*, 1396–1399. [CrossRef]
- 43. Xu, Y.; Zheng, G.; Yang, X.; Li, X. Rhodium(III)-catalyzed chemodivergent annulations between N-methoxybenzamides and sulfoxonium ylides via C–H activation. *Chem. Commun.* **2018**, *54*, 670–673. [CrossRef]
- 44. Zhu, J.; Sun, S.; Cheng, J. Rh(III)-catalyzed [4+1]-annulation of azobenzenes with α- carbonyl sulfoxonium ylides toward 3-acyl-(2H)-indazoles. *Tetrahedron Lett.* **2018**, *59*, 2284–2287. [CrossRef]
- 45. Ji, S.; Yan, K.; Li, B.; Wang, B. Cp*Co(III)-Catalyzed C–H Acylmethylation of Arenes by Employing Sulfoxonium Ylides as Carbene Precursors. *Org. Lett.* **2018**, *20*, 5981–5984. [CrossRef]
- Cui, X.F.; Ban, Z.H.; Tian, W.F.; Hu, F.P.; Zhou, X.Q.; Ma, H.J.; Zhan, Z.Z.; Huang, G.S. Ruthenium-catalyzed synthesis of indole derivatives from N-aryl-2-aminopyridines and alpha-carbonyl sulfoxonium ylides. *Org. Biomol. Chem.* 2019, *17*, 240–243. [CrossRef]
- 47. Wu, C.; Zhou, J.; He, G.; Li, H.; Yang, Q.; Wang, R.; Zhou, Y.; Liu, H. Ruthenium(II)-catalyzed selective C–H bond activation of imidamides and coupling with sulfoxonium ylides: An efficient approach for the synthesis of highly functional 3-ketoindoles. *Org. Chem. Front.* **2019**, *6*, 1183–1188. [CrossRef]
- 48. Vaitla, J.; Hopmann, K.H.; Bayer, A. Rhodium-Catalyzed Synthesis of Sulfur Ylides via in Situ Generated Iodonium Ylides. *Org. Lett.* **2017**, *19*, 6688–6691. [CrossRef]
- Talero, A.G.; Martins, B.S.; Burtoloso, A.C.B. Coupling of Sulfoxonium Ylides with Arynes: A Direct Synthesis of Pro-Chiral Aryl Ketosulfoxonium Ylides and Its Application in the Preparation of α-Aryl Ketones. *Org. Lett.* 2018, 20, 7206–7211. [CrossRef]
- 50. Janot, C.; Palamini, P.; Dobson, B.C.; Muir, J.; Aissa, C. Palladium-Catalyzed Synthesis of Bis-Substituted Sulfoxonium Ylides. *Org. Lett.* **2018**, *21*, 296–299. [CrossRef]
- 51. Jia, Q.; Kong, L.; Li, X. Cobalt(III)-catalyzed C–H amidation of weakly coordinating sulfoxonium ylides and α-benzoylketene dithioacetals. *Org. Chem. Front.* **2019**, *6*, 741–745. [CrossRef]
- Chen, X.; Wang, M.; Zhang, X.; Fan, X. Rh(III)-Catalyzed Cascade Reactions of Sulfoxonium Ylides with α-Diazocarbonyl Compounds: An Access to Highly Functionalized Naphthalenones. *Org. Lett.* 2019, *21*, 2541–2545. [CrossRef]
- Alhamadsheh, M.M.; Waters, N.C.; Sachdeva, S.; Lee, P.; Reynolds, K.A. Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. *Bioorg. Med. Chem. Lett.* 2008, 18, 6405–6420. [CrossRef]

Sample Availability: Not available.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).